Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Research results from R. Harrop and co-authors update knowledge of cancer vaccines
July 30th, 2008
"Modified vaccinia Ankara (MVA) encoding the tumor antigen 5T4 (TroVax((R))) has been evaluated in an open label phase II study in metastatic colorectal cancer patients. The primary objective was to assess the safety and immunogenicity of TroVax injected before, during and after treatment with 5-fluorouracil, leukovorin and irinotecan," researchers in Oxford, the United Kingdom report. "TroVax was administered to 19 patients with metastatic colorectal cancer. Twelve patients had blood samples taken following each of the six injections and were considered to be evaluable for assessment of immunological responses. Both antibody and cellular responses specific for the...
Source: Vaccine Weekly (2008-07-30)
|
